Patrick G. Enright

Patrick G. Enright is a declared insider at 5 companies (board member); the most frequent names are Jazz Pharmaceuticals plc, Vera Therapeutics, Inc. and Zenas BioPharma, Inc. Between 5 January 2016 and 5 August 2026, the trades on record add up to 36 filings.

Both buying and selling appear: 5 purchases worth €18.7M, against 19 sales worth €423k. The totals exclude 18 filings filed without an amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 7 share grants.

Half of the purchases are above €1.7M and half below. On 3 out of 5 purchases, another insider of the same company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. For 3 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 33% of cases, with a median move of -17.1%. Past outcomes like these are no guarantee of what comes next.

On 7 August 2026 came the latest disclosure, a share grant in Jazz Pharmaceuticals plc. The clock since the last published purchase (15 December 2025) now reads 307 days. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.